NCT06714396 - A Study Exploring the PK/PD Relationship of QRL-101 in Adults With ALS | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 11, 2024

Primary Completion Date

August 22, 2025

Study Completion Date

August 22, 2025

Conditions

Amyotrophic Lateral Sclerosis

Interventions

DRUG

QRL-101

Single doses of QRL-101 will be orally administered. The dose levels may change subject to available nonclinical, clinical, safety, and PK data.

OTHER

Placebo

Single doses of compartor placebo will be orally administered. The dose levels may change subject to available nonclinical, clinical, safety, and PK data.

Trial Locations (1)

9728 NZ

Universitair Medisch Centrum Utrecht, Utrecht

All Listed Sponsors

lead

QurAlis Corporation

INDUSTRY